AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stents
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition for CHF
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac transplant
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0
Study 7871179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemakers
Number of subjects: 0
Study 2032716 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b subcutaneously (s.c.) 5 x 10(6) IU three times weekly for four weeks
Number of subjects: 49
Study 2032716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7072623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin daily for 12 weeks
Number of subjects: 60
Study 7072623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30539771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic prediction using joint modelling
Number of subjects: 304
Study 30539771 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach using only baseline predictors
Number of subjects: 304
Study 27903298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) meal
Number of subjects: 18
Study 27903298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 18
Study 27903298 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) meal
Number of subjects: 18
Study 27903298 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of TNFα and IL-6 after HC meal
Number of subjects: 18
Study 24958479 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (subcutaneous, every 2 weeks for 12 weeks)
Number of subjects: 43
Study 24958479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous, every 2 weeks for 12 weeks)
Number of subjects: 43
Study 22042703 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.3 mg·kg(‐1)
Number of subjects: 178
Study 22042703 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 178
Study 20962598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the affected motor cortex
Number of subjects: 18
Study 20962598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation over the unaffected motor cortex
Number of subjects: 18
Study 20962598 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 18299070 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 36743
Study 18299070 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival cefuroxime
Number of subjects: 36743
Study 15695985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mifepristone (200 mg, administered orally)
Number of subjects: 65
Study 15695985 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (infusion)
Number of subjects: 65
Study 12733689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 172
Study 12733689 — intervention group
Group type: COMPARATOR
Intervention: Droperidol/Dimenhydrinate
Number of subjects: 172
Study 10761168 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine SR (4-aminopyridine)
Number of subjects: 25
Study 8931223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondissection method for autogenous vein grafting
Number of subjects: 86
Study 8507025 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.4 mL of 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 20
Study 8507025 — intervention group
Group type: COMPARATOR
Intervention: 4.4 mL of 3% prilocaine with 0.03 IU/mL felypressin
Number of subjects: 20
Study 3908331 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (100-400 mg)
Number of subjects: 24
Study 3908331 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40-160 mg)
Number of subjects: 24
Study 3908331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 24
Study 3543146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous chloroquine
Number of subjects: 60
Study 3543146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular chloroquine
Number of subjects: 60
Study 3543146 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous chloroquine
Number of subjects: 60
Study 3543146 — intervention group
Group type: COMPARATOR
Intervention: Oral chloroquine
Number of subjects: 60
Study 28648859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus macrolide
Number of subjects: 225
Study 28648859 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus placebo
Number of subjects: 225
Study 27120107 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional appendectomy with electro cauterization and silk suture for stump ligation
Number of subjects: 24
Study 27120107 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendectomy with LigaSure™ for stump closure
Number of subjects: 24
Study 27120107 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendectomy with Harmonic Scalpel™ for stump closure
Number of subjects: 24
Study 24947924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 205
Study 22793957 — intervention group
Group type: EXPERIMENTAL
Intervention: IMF for 2 weeks
Number of subjects: 2
Study 22793957 — intervention group
Group type: COMPARATOR
Intervention: IMF for 4 to 6 weeks
Number of subjects: 2
Study 20557362 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI-based triple therapy plus S. boulardii for 4 weeks
Number of subjects: 991
Study 20557362 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI-based triple therapy plus S. boulardii and DA-9601 for 4 weeks
Number of subjects: 991
Study 20557362 — intervention group
Group type: COMPARATOR
Intervention: PPI-based 7-day triple therapy
Number of subjects: 991
Study 18775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1125
Study 18775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 1125
Study 18775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1125
Study 18775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1125
Study 18775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1125
Study 18775645 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine vs Risperidone
Number of subjects: 1125
Study 16151466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) alone (2 x 10 mg/m2/day subcutaneously days 1-14)
Number of subjects: 180
Study 16151466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) plus granulocyte/macrophage colony stimulating factor (rhGM-CSF) (150 microg/day s.c. from day 8 to 21)
Number of subjects: 180
Study 16151466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) plus Interleukin-3 (IL-3) (150 microg/day s.c. from day 8 to 21)
Number of subjects: 180
Study 16151466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytosine arabinoside (LD-AraC) with GM-CSF or IL-3
Number of subjects: 180
Study 16151466 — intervention group
Group type: COMPARATOR
Intervention: Control group (LD-AraC alone)
Number of subjects: 180
Study 12483419 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg
Number of subjects: 48
Study 12483419 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunting
Number of subjects: 48
Study 12483419 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 48
Study 10840147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 9370836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl patient-controlled analgesia
Number of subjects: 254
Study 9370836 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine patient-controlled analgesia
Number of subjects: 254
Study 9370836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine patient-controlled analgesia
Number of subjects: 254
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 7.5 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 10 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 20 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 35 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 40 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 45 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 50 mg
Number of subjects: 28
Study 1606996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3896566 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily beclomethasone dipropionate (BDP)
Number of subjects: 36
Study 3896566 — intervention group
Group type: COMPARATOR
Intervention: Four times daily beclomethasone dipropionate (BDP)
Number of subjects: 36
Study 30796818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Number of subjects: 72
Study 30796818 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Number of subjects: 72
Study 30796818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV dose 1
Number of subjects: 72
Study 30796818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 29473247 — intervention group
Group type: EXPERIMENTAL
Intervention: D-methionine (100 mg/kg p.o. b.i.d.)
Number of subjects: 60
Study 26430819 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-enhanced CBT
Number of subjects: 163
Study 26430819 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Program (SBP)
Number of subjects: 163
Study 26430819 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT
Number of subjects: 163
Study 24249842 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including group exercise training twice a week and daily walks
Number of subjects: 18
Study 24249842 — intervention group
Group type: COMPARATOR
Intervention: Standardized information at discharge
Number of subjects: 18
Study 22067197 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake (standard breakfast 30 to 10 minutes prior to dosing)
Number of subjects: 55
Study 22067197 — intervention group
Group type: COMPARATOR
Intervention: Positive control (400 mg of moxifloxacin)
Number of subjects: 55
Study 21047410 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 5292
Study 17650935 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 22
Study 17650935 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN)
Number of subjects: 22
Study 16105374 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced occupational therapy support intervention
Number of subjects: 12
Study 16105374 — intervention group
Group type: COMPARATOR
Intervention: Practice-based intervention
Number of subjects: 12
Study 11882227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment (1 min)
Number of subjects: 52
Study 11882227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment (4 min)
Number of subjects: 52
Study 11882227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 52
Study 10902449 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% prilocaine (1 mg/kg, n = 27)
Number of subjects: 57
Study 10902449 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine (0.8 mg/kg, n = 30)
Number of subjects: 57
Study 9398880 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC1 (1 week of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Number of subjects: 70
Study 9398880 — intervention group
Group type: COMPARATOR
Intervention: LAC2 (2 weeks of 30 mg lansoprazole bid, 1 gm amoxicillin bid, and 500 mg clarithromycin bid)
Number of subjects: 70
Study 9398880 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC1
Number of subjects: 70
Study 9398880 — intervention group
Group type: COMPARATOR
Intervention: LAC2
Number of subjects: 70
Study 9398880 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC1 and LAC2
Number of subjects: 70
Study 1343606 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting episiotomy use in primiparous women
Number of subjects: 703
Study 1343606 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting episiotomy use in multiparous women
Number of subjects: 703
Study 1343606 — intervention group
Group type: COMPARATOR
Intervention: Liberal or routine use of episiotomy
Number of subjects: 703
Study 1343606 — intervention group
Group type: COMPARATOR
Intervention: Median episiotomy
Number of subjects: 703
Study 3891188 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day)
Number of subjects: 8
Study 3891188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (200 mg twice a day)
Number of subjects: 8
Study 3891188 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg a day)
Number of subjects: 8
Study 31055678 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 17
Study 31055678 — intervention group
Group type: COMPARATOR
Intervention: Concentric training (CON)
Number of subjects: 17
Study 28343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 3–6 mg/d
Number of subjects: 1065
Study 28343051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 9–12 mg/d
Number of subjects: 1065
Study 28343051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: High Threat, Loss Frame, No Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: High Threat, Gain Frame, No Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Threat, Loss Frame, No Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Threat, Gain Frame, No Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: High Threat, Loss Frame, Yes Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: High Threat, Gain Frame, Yes Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Threat, Loss Frame, Yes Choice
Number of subjects: 814
Study 25256920 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Threat, Gain Frame, Yes Choice
Number of subjects: 814
Study 23436693 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body weight‐supported treadmill training (12 weeks)
Number of subjects: 10
Study 23436693 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (12 weeks)
Number of subjects: 10
Study 22087222 — intervention group
Group type: EXPERIMENTAL
Intervention: Disci/Rhus toxicodendron compositum (verum)
Number of subjects: 150
Study 22087222 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 150
Study 22087222 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 150
Study 18992854 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,800 mg
Number of subjects: 8
Study 18992854 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 16856352 — intervention group
Group type: EXPERIMENTAL
Intervention: HRcon (constant heart rate)
Number of subjects: 7
Study 16856352 — intervention group
Group type: COMPARATOR
Intervention: HRvar (variable heart rate)
Number of subjects: 7
Study 12634023 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip-Hop to Health Jr. obesity prevention program
Number of subjects: 1098
Study 12634023 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1098
Study 10848918 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant celery profilin
Number of subjects: 17
Study 9152674 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 3150
Study 9152674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 3150
Study 9152674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 3150
Study 9152674 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (meta-analysis)
Number of subjects: 3150
Study 9152674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse cardiac events (general)
Number of subjects: 3150
Study 8515191 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching of the strategy
Number of subjects: 90
Study 8515191 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional training
Number of subjects: 90
Study 8515191 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 90
Study 3102585 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR, 360 mg
Number of subjects: 19
Study 29432408 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-Profile (ZP) anterior cervical discectomy and fusion (ACDF)
Number of subjects: 104
Study 29432408 — intervention group
Group type: COMPARATOR
Intervention: Traditional ACDF with anterior cervical plate (ACP)
Number of subjects: 104
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA fasting glucose concentration cutoff (5.6-6.9 mmol/L)
Number of subjects: 10844
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA HbA1c cutoff (5.7-6.4%)
Number of subjects: 10844
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: IEC HbA1c cutoff (6.0-6.4%)
Number of subjects: 10844
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO fasting glucose concentration cutoff (6.1-6.9 mmol/L)
Number of subjects: 10844
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA HbA1c cutoff
Number of subjects: 10844
Study 27863979 — intervention group
Group type: COMPARATOR
Intervention: ADA fasting glucose concentration clinical categories
Number of subjects: 10844
Study 27863979 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA HbA1c clinical categories
Number of subjects: 10844
Study 27863979 — intervention group
Group type: COMPARATOR
Intervention: WHO fasting glucose concentration clinical categories
Number of subjects: 10844
Study 27863979 — intervention group
Group type: COMPARATOR
Intervention: ADA and WHO 2 h glucose concentrations clinical categories
Number of subjects: 10844
Study 26359119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 662
Study 23472309 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-above-the-cuff tracheotomy tubes
Number of subjects: 18
Study 23472309 — intervention group
Group type: COMPARATOR
Intervention: Standard tracheotomy tubes (Control)
Number of subjects: 18
Study 21384219 — intervention group
Group type: EXPERIMENTAL
Intervention: Online care management through electronic messaging
Number of subjects: 208
Study 18354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intervention
Number of subjects: 0
Study 18354933 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of intervention
Number of subjects: 0
Study 18354933 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 17161044 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (PHF); administered within 6 hours of symptom onset by ambulance.
Number of subjects: 1095
Study 17161044 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis (PHF)
Number of subjects: 1095
Study 17161044 — intervention group
Group type: COMPARATOR
Intervention: Inhospital treatment
Number of subjects: 1095
Study 12679394 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐IMP‐ARG
Number of subjects: 39
Study 12679394 — intervention group
Group type: COMPARATOR
Intervention: H(2)(15)O PET
Number of subjects: 39
Study 10735799 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 microg sufentanil
Number of subjects: 42
Study 10735799 — intervention group
Group type: COMPARATOR
Intervention: 40 microg fentanyl
Number of subjects: 42
Study 9190053 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthreatening success condition
Number of subjects: 96
Study 9190053 — intervention group
Group type: EXPERIMENTAL
Intervention: Threatening failure condition
Number of subjects: 96
Study 9190053 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 96
Study 8999692 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter EKG monitoring during gastroscopic examination
Number of subjects: 0
Study 8999692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Holter EKG monitoring)
Number of subjects: 0
Study 2724276 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (linoleic acid supplementation)
Number of subjects: 0
Study 2724276 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil (placebo)
Number of subjects: 0
Study 31619274 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral nasal pressure applied intraoperatively for 5 minutes after lateral osteotomies
Number of subjects: 16
Study 31619274 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral nasal pressure applied intraoperatively
Number of subjects: 16
Study 28626589 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (Ex) and lunch labelled as low in fat (LF)
Number of subjects: 14